Back to Dashboard

KER-050-D301

AML-MDS•NCT06499285•Last updated: 2/17/2026

Recruiting

Study Design

Study Drug

Elritercept/ placebo

Mechanism of Action

tgf-β ligand

Sponsor

Unknown

Design

III

Control Arm

-

Criteria

Inclusion Criteria

very low-, low-, intermediate risk MDS

Age: ≥18 years Phase: III

Exclusion Criteria

Enrollment

Progress0 / 0

Contact Information

Principal Investigator

Unknown

Study Nurse

李佳玲

Contact Tel

4620